Sorrento Therapeutics (SRNE) 8-K Jefferies 2013 Global Healthcare Conference

Sorrento Therapeutics, Inc. (STI)

Next-Generation

Targeted and Personalized

Cancer Therapeutics

Jefferies 2013 Global Healthcare Conference

June 6, 2013

Exhibit 99.1

2

Safe Harbor Statement           OTC Symbol: SRNE

Pro Forma for

Merged Sorrento + IGDRASOL

This presentation contains "forward-looking statements," as that term is defined under the Private

Securities Litigation Reform Act of 1995 (PSLRA), including statements regarding expectations, beliefs

or intentions regarding our business, technologies and products strategies or prospects. Actual results

may differ from those projected due to a number of risks and uncertainties, including, but not limited to,

the possibility that some or all of the pending matters and transactions being considered by the

Company may not proceed as contemplated, and by all other matters specified in Company's filings with

the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining

regulatory approvals of new, commercially-viable and competitive products and product candidates.

These statements are made based upon current expectations that are subject to risk and uncertainty

and information available to the Company as of the date of this presentation. The company does not

undertake to update forward-looking statements in this presentation to reflect actual results, changes in

assumptions or changes in other factors affecting such forward-looking information. Assumptions and

other information that could cause results to differ from those set forth in the forward-looking information

can be found in the Company's filings with the Securities and Exchange Commission, including its most

recent periodic report. We intend that all forward-looking statements be subject to the safe-harbor

provisions of the PSLRA.

3

Oncology Product Candidates

G-MAB

®

Immuno-

therapy

mAbs

Cynviloq

™

Phase 3

Ready

AfDC

Next-Gen

ADC

4

TUMOR

Abraxane

®

ADC

(Adcetris

®

, Kadcyla™

)

Combo Therapy

(Abraxane

®

+ Avastin

®

)

The Target Oncology Markets

mAb

(Avastin

®

, Herceptin

®

, Yervoy

®

)

+

5

Significant Value Drivers

Abraxis/Celgene

Genentech

Cambridge Antibody Technology

Seattle Genetics (SGEN): ~$4B Market Cap

Immunogen (IMGN): ~$1.5B Market Cap

Abraxane

®

MBC approval

Abraxis acq’d by

Celgene for $3B+

Abraxane

®

NSCLC approval

Abraxane

®

MBC sales:

$427M

Abraxane

®

PC

approval (exp’d)

2005

2010

2012

2013

Genentech acq’d by

Roche for ~$106B

Avastin

®

+

Herceptin

®

(~$12B)

Humira

®

(~$10B)

2009

2013

Adcetris

®

approval

2013

2011

KADCYLA

®

approval

2006

CAT acq’d by

AZ for $1.3B

Abraxane

®

mAbs

ADC

6

TUMOR

G-MAB

®

Cynviloq™

+ G-MAB

®

Next Generation Cancer Therapeutics

Cynviloq™

•

High-diversity, human Ab library

•

10+ lead mAb programs

•

Immunotherapies

(Oncology, non-oncology and rIVIG)

•

FTO and no stacking royalty

•

Paclitaxel

polymeric micelle

•

Phase 3-ready

•

Competitive vs.

Abraxane

®

•

Single source

•

Combination therapy

•

No stacking royalty

•

Single source

•

G-MAB

®

or biosimilar mAbs

•

Proprietary formulation

+

AfDC:

Antibody formulated Drug Conjugate

7

INDICATION

INDICATION > TARGET

G-MAB

®

Metastatic Breast Cancer (505(b)(2) BE)*

Non-Small Cell Lung Cancer (505(b)(2) BE)*

Bladder Cancer (sNDA)

Ovarian Cancer (sNDA)

Pancreatic Cancer (505(b)(2) BE)*

Oncology > PD-L1, PD-1, other

Inflammation > PD-L1, CCR2, other

Infectious Disease > MRSA

Q4 2013

Q4 2013

H1 2015

H1 2015

AfDC

Oncology > c-Met, CXCR5, other

Q4 2013

H1 2015

*

Subject to EOP2 meeting with FDA scheduled for Q3 2013

Multiple Strategic Partnership Opportunities

H1 2014

2016

H1 2015

H2 2015

Pipeline

Cynviloq™

8

Management Team

8

Henry Ji, Ph.D.

President, CEO & Director

•

Inventor of STI G-MAB

®

Technology

•

President & CEO of Stratagene Genomics

•

VP of CombiMatrix and Stratagene

CombiMatrix, Stratagene,

Stratagene Genomics,

Human Genome Sciences

Vuong Trieu, Ph.D.

Chief Scientific Officer

•

Founder and CEO of Igdrasol

•

Instrumental

in

the

approval

of

Abraxane

®

•

Co-inventor

of

IP

covering

Abraxane

®

•

Led and developed the pipeline for Abraxis Biosciences

resulting in its sale for $2.9B

Abraxis BioScience (ABI), 

Celgene, AME (Eli Lilly),

Genetic Therapy Inc.

(Novartis)

George Uy

Chief Commercial Officer

•

Directed

the

highly

successful

launch

of

Abraxane

®

,

Xeloda

®

& Fusilev

®

•

Built commercial infrastructures and organizations in

startup companies

ABI, Spectrum Pharma,

Hana Biosciences, Roche

Jaisim Shah

Chief Business Officer

•

$430M sale of Elevation Pharmaceuticals to Sunovion-

Dainippon

•

$1.15B PDL-BMS global collaboration

•

$800M PDL-Biogen Idec collaboration

•

$200M sale iv Busulfex to Otsuka

Elevation, Roche, BMS,

Facet Biotech, PDL, Cytrx,

Zelos

Richard Vincent

CFO and Director

•

$430M sale of Elevation to Sunovion-Dainippon

•

Meritage Pharma option agreement with ViroPharma

($90M upfront + milestones)

•

$310M sale of Verus Asthma program to AZ

•

Elan: various acquisitions and divestitures with

aggregate values in excess of $300M

Elevation, Meritage,

Suneva Medical, Verus,

Women First Healthcare,

Elan, Phase Metrics,

Deloitte & Touche

9

Oncology Franchise

Phase 3

candidate

Cynviloq™

10

What is Cynviloq™?

Proprietary Paclitaxel Polymeric Micelle

paclitaxel

Poly(ethylene glycol)

hydrophilic shell

Poly(D,L-Lactide)

hydrophobic core

Cynviloq™

10

Mean size

80 nm

Cynviloq™

paclitaxel

polymeric micelle

Chemical

polymer:

Poly-lactide and polyethylene

glycol diblock copolymer

Mean size

130 nm

Biological

polymer:

Donor-derived human serum

albumin (HSA)

260 mg/m

2

Taxol

®

paclitaxel

Cremophor

EL

excipient:

Polyoxyethylated

castor

oil

Formulation

Generation

175 mg/m

2

Maximum Tolerated

Dose (MTD)

Evolution of Paclitaxel Therapy

11

1

2 

3

Abraxane

®

-paclitaxel

300

mg/m

2

st

nd

rd

nab 

12

Cynviloq™

Taxol

®

Abraxane

®

Cynviloq™

Advantage

Maximum

Tolerated

Dose

(mg/m

2

)

>300

175

260

Potential for

higher efficacy

Rapid reconstitution:

no foaming concerns

Convenience for

busy practices and

pharmacies

No donor-derived human

serum albumin (HSA)

No viral / prion

concerns

Convenient storage

conditions

No requirement for

controlled temp

storage

No microbial growth

Chemical polymer

Cremophor-free

Reduced side effects

Advantages vs. Competitors:

Taxol

®

& Abraxane

®

Taxol

®

is

a

registered

trademark

with

Bristol-Myers-Squibb.

Abraxane

®

is

a

registered

trademark

with

Celgene.

13

•

>300 mg/m²

(q3w) vs. 175 mg/m²

(Taxol

®

; weekly) and 275 mg/m

²

(Abraxane

®

; q3w)

•

Data suggestive of efficacy comparable to historic data for

Abraxane

®

and superior to historic Taxol

®

data or Standard-of-Care

•

Possible Phase 3 sNDA programs in these tumor types

•

GPMBC301.  An Open-label, Randomized, Parallel, Phase 3 Trial to Evaluate the

Efficacy and Safety of Genexol-PM

®

Compared to Genexol

®

(Paclitaxel with

Cremophor EL) in Subjects with Recurrent or Metastatic BC; n=105

(Genexol-PM

®

); n=104 (Genexol

®

)

•

Interim analysis suggests ORR superior to Taxol

®

and comparable to historic

Abraxane

®

efficacy

•

Efficacy and safety data supportive of 505(b)(2) BE submission

•

Efficacy and safety data supportive of 505(b)(2) BE submission

Clinical Efficacy & Safety Summary

Cancer Center, Russia, S. Korea)

Trials

established

higher

MTD

(total

n=80;

in

US

-

Dana

Farber

Cancer

Inst.,

Russia, S. Korea)

Completed

trials

in

MBC,

NSCLC,

PC,

OC,

BC

(total

n=259;

in

US

–

Yale

Phase 2:

Phase 1:

Ongoing trial for MBC

(n=209; in S. Korea)

Phase 3:

Completed for MBC and NSCLC (total n=502)

PM-Safety:

Total number of patients across all trials: 946

14

Comparison of Clinical Efficacy in MBC:

Phase 3 Trials

Overall

Response

Rate

(%)

US

approval

for

Abraxane

®

in

MBC

and

NSCLC

for

non-inferiority

against

Taxol

®

based

on

ORR

*

No

obvious

ethnic

differences

seen

between

ORR

in

trials

*  Interim data from trial; OS and PFS analyses ongoing 

United States

Cynviloq™

Taxol

®

Abraxane

®

CA012

Abraxane

®

CA201

Taxol

®

Taxol

®

China

South Korea*

p = 0.03

p = 0.001

p = 0.025

0

5

10

15

20

25

30

35

40

45

n=105

n=104

n=209

n=205

n=81

n=82

15

Abraxane

®

nanoparticles

at concentrations above its critical

micelle concentration*

* Data on file

FBS = fetal bovine serum

Paclitaxel released

from

both

formulations

binds

to

albumin

in

the

blood

and

exploits

albumin-transport

pathway

into

the

tumor

Cynviloq™

polymeric micelles

at concentrations above its critical

micelle concentration*

Absence of nanoparticles at

physiological concentration

Absence of nanoparticles at

physiological concentration

Size (nm)

Nanoparticle Disintegration

Size (nm)

g/mL

16

Cynviloq™

data on file

*

Gardner et all, 2008

•

PK BE was calculated as 95% confidence interval (CI)

•

Ratio T/R (Cmax and AUCinf) within 80-125% (90% CI)

Comparison of mean non-compartmental pharmacokinetic parameters of

Cynviloq™

(T) and Abraxane

®

(R) @ 260 mg/m

2

with 30 min infusion time:

C

max

(ng/mL)

Ratio

C

max

(T)/C

max

(R)

AUC

inf

(ng*h/mL)

Ratio

AUC

inf

(T)/AUC

inf

(R)

Cynviloq

TM

(Simulated PK)

19486

99.6%

22198

109.2%

Abraxane

®

(Actual PK)*

19556

20324

Simulated PK Parameters Supportive

of

505(b)(2)

BE:

Cynviloq™

vs.

Abraxane

®

17

•

•

•

EOP2 meeting with FDA to discuss BE protocol and site selection

(Q3 2013)

•

Initiate BE studies (Q4 2013)

-

One cross-over study (n=66)

at dose of 260 mg/m

2

-

12 months duration

-

~$3M

•

NDA filing (H1 2015)

•

FDA approval for all current (H1 2016 for MBC and NSCLC) and

future Abraxane

®

(PC and MM) indications

STI’s

Business

Strategy

505(b)(2) BE Timeline

17

BE Registration Trial and Commercial Launch for MBC / NSCLC

EU Rights for Partnership

18

Cynviloq™

Phase 2 (Korea)*

n=34

#

Best Supportive Care (BSC)

Phase 2 (Japan) **/ Phase 3 (EU)***

n=23** / n=108***

2

line

260

mg/m

(cycle

1)

300

mg/m

(cycles

2-4)

q3w

Designed to prevent and

control the side effects of

cancer and its treatment

Overall Response Rate

21%

-

/ 0%***

Progression Free Survival

2.7 M

-

/ 1.5 M***

Overall Survival

6.5 M

2.3 M** / 4.3 M***

*

Invest

New

Drugs

(2012)

30:1984–1990

# advanced urothelial carcinoma patients  refractory to gemcitabine and cisplatin

**

AUA-

San

Diego

May

4th-8

th

;

***

JCO

(2009):

4454-61

Summary:

•

High

unmet

need

with

no

FDA

approved

2

nd

line

drug

•

Generally well-tolerated and demonstrated clinical ORR

•

Phase

3-ready

for

development

as

2

nd

line

chemotherapy

in

patients

refractory to platinum-based therapy

Cynviloq™

Bladder

Cancer

-

vs.

Historic

BSC

Clinical

Experience:

2

2

nd

19

•

Registration Trial and Commercial Launch for BC

•

EU Rights for Partnership

STI’s

Business

Strategy

sNDA Timeline for Bladder Cancer

•

Phase 3 study preparation (Q3 2013)

-

No approved 2nd line treatment; ~15,000 deaths annually (US)

•

Orphan Drug Status Designation (Q4 2013)

-

7-year marketing exclusivity

-

Enhanced R&D credit

•

“First Patient In”

(H1 2014)

-

n=400 (~200 patients each arm) vs. BSC

-

18-24 months duration

-

$20M

•

505(b)(2) sNDA filing for 2nd line treatment (H1 2016)

19

20

Therapeutic Antibody Engine

G-MAB

®

Immuno-

therapy

mAb

candidates

21

•

Proprietary amplification

–

RNA amplification for

variable domains

STI Technology

•

Very high diversity:

V

H

: 7.1 x 10

7

V

L

: 2.9 x 10

8

Combined: 2.1 x 10

16

•

High successful hit rate

Library Quality

•

FTO

•

Issued and pending

patents on G-MAB

®

library and individual

mAbs

•

No royalty burden

Intellectual

Property

G-MAB

®

Library

Difficult targets: GPCR

22

Potent

mAbs

Generated

From

G-MAB

®

Library

Difficult Targets:

Small Molecules

Low molecular weight antigens

(< 2,500 Da; “haptens”)

Validated and/or Hot Targets:

Medium-sized antigens

Soluble protein ligands

or cell surface receptors

Most Difficult Targets:

Large Complex Molecules

G protein-coupled receptors

(GPCRs)

•

Auto-Inducing Peptides (AIPs)

-

Methicillin-resistant S. aureus

(MRSA)

-

Clostridium difficile

(C.diff)

•

PD-L1

•

PD-1

•

c-Met

•

VEGFR2

•

EGFR

•

ErbB3

•

CCR2

•

CCR6

•

CXCR3

•

CXCR5

Size of Target Antigen

23

Days After Disease Induction

STI-B0201 (D1) -

prophylactic

STI-B0201 (D1) -

therapeutic

PBS

Inflammation: Anti-CCR2 mAb Efficacious in

Multiple Sclerosis (EAE) Model

Summary:

•

STI-B0201

identified

from

G-MAB

®

library

has

superior

binding

properties

to

CCR2

compared to competitor mAb

•

STI-B0201 stabilizes disease when given prior to or after onset of symptoms

mAb

Cell Binding -

hCCR2

(EC

50

–

nM)

STI-B0201 (D1)

0.17

MLN1202

21

24

Immunotherapy: Anti-PD-L1 mAbs Exhibit Potent

Immune Modulation In Vitro

Summary:

STI

anti-PD-L1

mAbs

identified

from

G-MAB

®

library

at

least

as potent as competitor’s mAb (best listed in patent) 

C)

Anti-PD-L1 mAbs trigger:

A)

Enhancement of T cell activation

B)

Increased interleukin-2 (IL-2)

C)

Increased interferon-

(IFN-

)

A)

B)

25

Immunotherapy: Anti-PD-1 mAbs Exhibit Potent

Immune Modulation In Vitro

Summary:

STI

anti-PD-1

mAbs

identified

from

G-MAB

®

library

at

least

as potent as competitor’s mAb (best listed in patent) 

B)

C)

A)

Anti-PD-1 mAbs trigger:

A)

Enhancement of T cell activation

B)

Increased interleukin-2 (IL-2)

C)

Increased interferon-

(IFN-

)

26

Multiple Strategic Partnership Opportunities

ONCOLOGY

PD-L1

INFLAMMATION

ONCOLOGY /

INFLAMMATION

(GPCR)

INFECTIOUS

DISEASE

PD-1

c-Met

VEGFR2

EGFR

ErbB3

PD-L1

RAGE

CGRP

CCR2

CXCR3

CXCR5

MRSA

CCR6

(STI-A100X)

(STI-A110X)

(STI-A060X)

(STI-A020X)

(STI-A050X)

(STI-B010X)

(STI-B120X)

(STI-B150X)

(STI-B020X)

(STI-A120X)

(STI-B030X)

(STI-C020X)

(STI-B100X)

(STI-A0168)

H1 2015

H2 2015

G-MAB

®

Pipeline

H1 2015

27

Antibody formulated Drug Conjugate (AfDC)

AfDC

Next-Gen

ADC

28

AfDC Advantage

Requires:

•

Prodrug synthesis

•

Linker chemistry

•

ADC internalization

Drug released

in cancer cell

Enables:

•

Single source

•

Drug formulation

•

mAb-payload combinations

Drug released

in TUMOR

28

ADC

AfDC

STI’s

Business

Strategy

•

Advance 1 AfDC Project/Year to Clinical Proof-of-Concept

•

Strategic Partnerships

29

Xenograft

model

–

5x10

6

U118 human glioblastoma cells

treatment

initiated

Days After Tumor Inoculation

STI-A0601 (A1)

STI-A0602 (E1)

STI-A0603 (H8)

PBS

Oncology: Anti c-Met mAbs Exhibit Potent

Anti-Tumor Activity In Vivo

Summary:

STI

mAbs

identified

from

G-MAB

®

library

all

demonstrate potent suppression of tumor growth.

0

100

200

300

400

500

600

700

800

900

1000

7

10

12

14

17

19

21

24

26

28

31

33

35

30

AfDC

Opportunities

Multiple Strategic Partnership Opportunities

B-W-B (Bio-Way-Better) Candidates

EGFR

(Erbitux

®

)

Her2

(Herceptin

®

)

CD20

(Rituxan

®

)

VEGFR2

EGFR

c-Met

ErbB3

IGF-1R

CXCR5

CXCR3

Biosimilar

mAb

G-MAB

®

31

Positioning to Become an Oncology Leader

Cynviloq

™

G-MAB

®

AfDC

Next-Gen

ADC

Immuno-

therapy

mAbs

Phase 3

Ready

Sorrento

Therapeutics,

Inc.

(SRNE)

32

33

Sorrento Therapeutics, Inc. (SRNE)

Next-Generation

Targeted and Personalized

Cancer Therapeutics

Contact:

Henry Ji

President and CEO

hji@sorrentotherapeutics.com

(858) 668-6923